Compare Apollo Global Management Ord Shs (APO) vs 10X Genomics Inc (TXG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Apollo Global Management Ord Shs vs 10X Genomics Inc — how do they compare? Apollo Global Management Ord Shs trades at $120 (market cap $69.38B), while 10X Genomics Inc trades at $42.26 (market cap $5.43B). The key difference: Apollo Global Management Ord Shs is far larger — about 12.8× 10X Genomics Inc's market cap, and Apollo Global Management Ord Shs pays a 1.87% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| APO | TXG | |
|---|---|---|
Market Cap | $69.38B | $5.43B |
Sector | Financials | Health |
52-Week High | $156.05 | $43.10 |
52-Week Low | $100.30 | $11.34 |
Enterprise Value | -$168.19B | $4.97B |
Dividend Yield | 1.87% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Apollo Global Management (APO) trades at $120.34, up 0.42% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported Q1 2026 EPS of $1.94, beating estimates, and maintains strong analyst support with 23 buy ratings. Recent news highlights private credit growth opportunities alongside liquidity concerns in Apollo's funds.
APO's outlook is supported by earnings beats and a $149.86 consensus price target, but risks include private credit liquidity pressures and a high P/E ratio of 75.69. Investor sentiment is mixed due to ongoing fund withdrawal caps and legal investigations, though long-term growth in alternative assets remains a positive catalyst.
TXG trades at $42.73, down 0.86% today, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue growth and beat EPS estimates, with net losses narrowing significantly from -$166M in 2022 to -$44M in 2025. Recent collaborations with Cleveland Clinic and the acquisition of Proteintech Genomics highlight strategic expansion in diagnostics and multiomics capabilities.
Outlook remains cautiously optimistic as improving margins and cash flow support growth, but high valuation multiples and persistent net losses pose risks. Analyst consensus is mixed with a $35.14 price target below current levels, suggesting limited near-term upside despite positive operational trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apollo Global Management Ord Shs
Apollo Global Management Inc is an alternative investment manager. It serves various sectors such as chemicals, manufacturing and industrial, natural resources, consumer and retail, consumer services, business services, financial services, leisure, and media and telecom and technology. The company operates in three business segments that are Private Equity, Credit, and Real Assets. It generates maximum revenue from the Credit segment in the form of fees. The credit segment primarily invests in non-control corporate and structured debt instruments including performing, stressed and distressed instruments across the capital structure. It also includes Corporate Credit
Read more on APO →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
